The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
The pleiotropic effects of statins
Abstract
PURPOSE OF REVIEW: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the most widely prescribed drugs worldwide for lowering cholesterol levels. In use for more than 15 years, they have demonstrated efficacy, safety, and tolerability across a broad range of patients. This class of drugs has been designed to lower the cholesterol level by competitively inhibiting the enzyme responsible for its biosynthesis and thereby to play a major role in reducing cardiovascular risk. However, both basic evidence and clinical evidence also supports the idea that reductions in cardiovascular risk are dependent on mechanisms beyond cholesterol reduction alone, such as the reduction of endothelial dysfunction, inhibition of inflammatory responses, stabilization of atherosclerotic plaques, and modulation of procoagulant activity and platelet function. RECENT FINDINGS: In fact, as shown in several clinical trials, the beneficial effects of statin treatment begin earlier than its cholesterol-lowering effect. These other mechanisms could act in concert with the potent low-density lipoprotein cholesterol-lowering effects of this class of drugs to exert early and lasting cardiovascular protective effects. Recently, several studies have shown that an intensive lipid-lowering regimen with a statin provides greater protection against death or major cardiovascular events than does a standard regimen. SUMMARY: This review summarizes the new findings in these pleiotropic effects and describes their impact on vascular processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Platelet Activation in Unstable Coronary Disease
Fitzgerald, D. J., Roy, L., Catella, F., & FitzGerald, G. A. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610163151602 · Cited by 1,141
Ridker, P. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.028 · Cited by 290
Cited by
Lindahl, B., Baron, T., Erlinge, D., Hadziosmanovic, N., Nordenskjöld, A., Gard, A., & Jernberg, T. (2017) · Circulation · doi:10.1161/circulationaha.116.026336 · Cited by 482
The Nrf2 System as a Potential Target for the Development of Indirect Antioxidants
Jung, K.-A., & Kwak, M.-K. (2010) · Molecules · doi:10.3390/molecules15107266 · Cited by 474
Flint, A. C., Conell, C., Ren, X., Kamel, H., Chan, S. L., Rao, V. A., & Johnston, S. C. (2017) · Stroke · doi:10.1161/strokeaha.117.017343 · Cited by 56
Could statins constitute a novel treatment for endometriosis? Systematic review of the literature
Gibran, L., Maranhão, R. C., Abrão, M. S., Baracat, E. C., & Podgaec, S. (2014) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2014.05.028 · Cited by 29
Metadata
- Authors
- Calabr??, P., & Yeh, E. T. H.
- Venue
- Current Opinion in Cardiology
- Published
- 2005-11
- Volume
- 20
- Issue
- 6
- Pages
- 541-546
- ISSN
- 0268-4705 (ISSN-L)
- OpenAlex
- W2043470383
- Cited by
- 182
- References
- 7
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pleiotropic effects of statins. https://app.cochat.ai/papers/10.1097/01.hco.0000181482.99067.bf
- The paper
- Calabr??, P., & Yeh, E. T. H. (2005). The pleiotropic effects of statins. Current Opinion in Cardiology. https://doi.org/10.1097/01.hco.0000181482.99067.bf
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.